and SYK expression after 5-aza-dC treatment. These observations indicate that silencing of the B-cell-specific genes in cHL may be the consequence of a compromised regulatory network, were down-regulation of a few master transcription factors results in silencing of numerous genes.
INTRODUCTION B-cell-type Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL) are characterized
by either the complete absence or only low-level expression of many B-cell-specific genes. Whereas initially this was seen for Ig (immunoglobulin)-genes and specific cell surface markers, later analyses also identified the lack of a variety of B-cell-specific transcription factors like Oct2 (octamer binding factor 2), BOB.1/OBF.1 (B-cell Oct binding protein/Oct-binding factor), and PU.1(purine-reach GGAA binding site) (for review see 1 ). Recent gene expression array studies on cHL cell lines added to the list of down-regulated genes or confirmed the down-regulation of CD79a and CD79b, CD19, CD20, SYK (spleen tyrosine kinase),
BCMA (B-cell maturation antigen), LCK (lymphocyte-specific protein tyrosine kinase) and some others 2, 3 .
Extensive immunohistochemical studies in primary tumors by and large were in agreement with the gene expression array data obtained from cHL cell lines 4, 5 . These findings gave rise to the concept of "loss of the B-cell identity" as part of the neoplastic transformation process leading to cHL 1 .
Many of the affected genes are involved in regulation of the death/survival choice in B-cells upon BCR (Bcell receptor) activation. The BCR is made up from immunoglobulin heavy and light chains as well as CD79a
and CD79a. CD19 is a B-cell co-receptor that augments the signals delivered through the BCR 6 . CD20 is a non-glycosylated phosphoprotein expressed on the surface of almost all normal and malignant B cells. CD20
probably functions as a store-operated calcium channel, activation of which can lead to apoptosis 7 . LCK is involved in signal transduction and regulation of apoptosis induced by anti-CD20 antibody stimulation 8 . SYK is a protein kinase proximal to BCR involved in activating PLCγ2 (phospholipase Cγ2) 9 . Activation of PLCγ2 then results in Ca 2+ release. The stimulation of SYK, PLCγ2, and Ca 2+ release are necessary both for BCRsignaling and BCR-induced apoptosis 10, 9 .
The mechanisms of simultaneous down-regulation of many B-cell-specific genes in cHL are still not understood. In theory, gene silencing could be achieved by specific mutations, absence of transcription factors, or by epigenetic silencing. These processes may operate alone or in combination. Down-regulation of a large set of genes can be explained by the inhibition of few critical transcription factors. Indeed, several of the down-regulated genes listed above are regulated by BOB.1/OBF.1/Oct2 and/or PU.1 11, 12 . Genetic mutations as the cause of simultaneous silencing of numerous genes seem unlikely considering their relative scarcity and their mainly stochastic nature. Apparently, mutations and translocations of the genes, playing a crucial role in the pathogenesis of non-Hodgkin lymphomas are rare or absent in cHL 13 . Genomic imbalances or rearrangements are not the causes of PU.1, BOB.1/OBF.1, and Oct2 silencing in cHL 14 . The only known consistent oncogenic feature of cHL, the constitutive NF-κB activation, can be explained in only few cases by mutations of a regulatory gene 15 . Even the recently described mutations of the tumor suppressor gene SOCS-1 in about 40% of primary cHL cases 16 is most likely not the only tumorigenic mechanism.
In malignant neoplasias, epigenetic events often cause the down-regulation of tumor suppressor genes (for review see [17] [18] [19] [20] 25 . We found that inhibition of immunoglobulin transcription in cHL cells may at least in part be explained by epigenetic silencing 26 . The fact that epigenetic silencing often is non-random, but can occur in a pathway-specific manner and affect numerous genes 27,28 led us to ask whether this mechanism might be involved in down-regulation of B-lineage genes in HRS cells of cHL. Probing cHL cell lines, we show that this is indeed the case. Additionally, by analyzing microdissected cells we found that promoter methylation is not a cell culture artifact but is detectable also in primary cHL HRS cells.
Material and Methods

Cell lines and treatments
The human Burkitt lymphoma cell lines Namalwa and BJAB, as well as the cHL-derived cell lines L1236, KM-H2 and L428 were cultured in RPMI 1640 medium (Life Technologies, Karlsruhe, Germany)
supplemented with 10% fetal bovine serum (PAN, Biotech, Aidenbach, Germany), antibiotics, L-glutamine and 50 μM of 2-mercaptoethanol at 37 °C and 5% CO 2 . 5-aza-2´-deoxycytidine (5-aza-dC) was purchased from Calbiochem (Darmstadt, Germany 
RT-PCR
Total RNA was isolated from 1x10 6 cells using High Pure RNA Isolation Kit (Roche, Mannheim, Germany). °C. The PCR products were resolved on 1.5% agarose gel and stained with EtBr.
Methylation specific PCR (MSP)
The primers inside of the BOB.1/OBF.1 CpG island were located using the MethPrimer program 36 . Genomic DNA was isolated as described above. One μg of DNA was used for bisulfite modification using the CpGenome DNA modification kit, #S7820 (Chemicon, Temecula, CA) according to manufacturers instructions. 100 ng of the bisulfite converted DNA was amplified x35 using primers specific for methylated 
Bisulfite sequencing
To analyze DNA methylation in macro-samples (cell cultures or tissue samples), genomic DNA was isolated and non-methylated cytosines were converted to uridines by bisulfite treatment as described above. 100 ng of the templates were amplified with specific primers.
SYK promoter CpG island: GTTTGTGGGTTTTGGGTAGTTATAG and ACTCTTCCTCATTTTAAACAACTTCC, 57 °C.
BOB.1/OBF.1 promoter CpG island: GTTTTTGGGTTTATAATTGGTTTG and AAACTTTTTAAAAACCTAAATTCCC, 57 °C.
The HotStarTaq polymerase master kit (Qiagen) was used followed by 20 amplification cycles with Pwo DNA polymerase (Roche, Mannheim, Germany) to blunt the ends. PCR products were then cloned into the (Arcturus, Mountain View, CA) and purified with phenol/chloroform. Cytosines were deaminated by the bisulfite conversion protocol as described 37 . Deaminated DNA was desalted by QiaexII gel extraction kit (Qiagen) and desulfonated as described 37 . The DNA was precipitated with ethanol. The pellet was resuspended in 10 μL of water. The whole sample was PCR amplified using HotStarTaq polymerase master kit (Qiagen) (35 cycles) followed by 20 cycles with Pwo DNA polymerase (Roche) to blunt the ends. For
CD79b amplification we used primers GGTTTTAATTTGTATGGTAGGAAGG and CCAATAACTAAACACAAAAAACAAC, 49 °C. For SYK and BOB.1/OBF.1 CpG island amplification we used semi-nested primers. First the converted DNA was amplified with 35 cycles with respective outer primers (described in "Bisulfite sequencing "). 2 μL of the reaction were then amplified with a new nested forward primer and the same reverse primer (see above). The PCR products were cloned and sequenced as described for macro-samples. Nested forward primer for SYK GGGTAGTTTTATTTTTTTTGTTTG, 52 °C, and for BOB.1/OBF.1 GGTTTTTATAGTTTGTTTTATATTATTAAAA, 56 °C, were used.
RESULTS
Reactivation of silenced genes by 5-aza-dC
As outlined above, expression of multiple B-cell-specific genes had been shown to be down-regulated in primary HRS and cHL cell lines. Before we went on to check the potential involvement of epigenetic processes in this down-regulation we first confirmed the lack of expression of these genes in several cHL-derived cell lines. We chose the transcription factors BOB.1/OBF.1, and PU.1 as well as several genes encoding proteins involved in signaling (CD79b, CD19, CD20, BCMA, Syk, and Lck).
Expression of the selected genes was assessed in the cHL cell lines KM-H2, L1236, and L428. These cell lines share many properties of primary HRS cells 38, 39 . The Burkitt lymphoma cell lines Namalwa and BJAB were used as positive controls (Figure 1a ).
Whereas expression of all the genes tested was readily detectable in the Burkitt lymphoma cell lines, no significant expression for most of the Blineage-specific genes was detected in cHL-derived cell lines. However, consistent with our earlier observations L1236 cells showed expression of BOB.1/OBF.1 mRNA.
We then asked whether epigenetic silencing might contribute to the lack of expression of these genes in the cHL-derived cell lines. Cells were treated with 1 μM of 5-aza-dC for 24 h and subsequently were washed and incubated in complete medium for additional 72 h ( Figure 1B ). We found that over-expression of Oct2 alone did not reactivate PU.1 expression, whereas treatment of L428-Oct2 cells with 5-aza-dC resulted in appearance of the PU.1 signal (Figure 2A ).
However, Oct2 did not increase expression of CD20 and BCMA, which had shown only partial reactivation by 5-aza-dC in L428 cells ( Figure 1B and data not shown). relative to the start of transcription. PU.1 has also been identified previously as a positive regulator of its own promoter suggesting a positive autoregulatory loop 42 . We therefore asked whether the endogenous SYK and PU.1 genes in L428 cells could be reactivated by ectopic expression of PU.1. We used mouse PU.1 which shares substantial homology with the human PU.1 and is able to activate target promoters of human PU.1 43 .
By RT-PCR we found that in combination with 5-aza-dC treatment mouse PU.1 reactivated expression of the endogenous PU.1 and SYK genes ( Figure 2B ). Of note, ectopic PU.1 was able to reactivate SYK expression even without 5-aza-dC treatment. However, PU.1 alone or in combination with 5-aza-dC again was unable to further activate CD20 and BCMA (data not shown). Thus, re-expression of silenced genes induced by 5-azadC is dependent on the presence of specific transcription factors. Figure 3A . We found that in the PU.1, CD19, and SYK promoters the 5´-CCGG-3´motifs were always methylated in cHL cell lines but not in Burkitt lymphomas ( Figure 3B) . Absence of the PCR product in the samples digested with the methylation-insensitive enzyme MspI indicates that the 5´-CCGG-3´ sequence is preserved in the amplified regions.
Hypermethylation of
For analysis of BOB.1/OBF.1 CpG island methylation we used methylation-sensitive PCR (MSP) 45 . We SYK was chosen based on: (a) the presence of the well studied CpG island spanning the 5´-regulatory region and the first exon, which was found to be hypermethylated in various types of tumors 35, 46, 47 ; (b)
its known tumor-suppressor activity, and (c) participation in oxidative stress-mediated apoptosis in B-cells 48, 49 .
In the cHL cell lines a very high level of methylation was observed. Only in L1236 cells we found some unmethylated alleles. In contrast to the situation in cHL lines, methylated CpG dinucleotides were seen infrequently in the Burkitt lymphoma cell lines ( Figure 5 ). Therefore, these results on CpG island methylation were in agreement with the results described above ( Figure 3 ). Given the fact that hypermethylation can arise as a consequence of cell culture 50 51 , we wanted to move this analysis to primary HRS cells. We first analyzed SYK methylation in normal peripheral B-cells (PBL) and in normal tonsil tissue ( Figure 5 ). In these samples, the promoter region was predominantly hypomethylated whereas methylated alleles were rare (see PBL3 and TON N, Figure 5 ). We then analyzed the methylation pattern of the SYK CpG island in HRS cells from 3 cases of the primary cHL. Because HRS cells comprise only 1-2% of the tumor mass, we used laser capture microdissection to isolate about 100 HRS cells from each sample. We found that in 2 of 3 cHL the SYK CpG island was hypermethylated in more then 50% of the clones. Only in one cHL tumor specimen hypomethylated alleles prevailed ( Figure 5 ). Thus, in contrast to the preferentially hypomethylated status of SYK CpG island in normal tissue, the HRS cells of cHL were predominantly hypermethylated.
Next, we investigated the BOB.1/OBF.1 and CD79b methylation status using genomic bisulfite sequencing in isolated HRS cells. CD79b is interesting because it does not have a bona fide CpG island in the vicinity of the promoter, but its silencing correlated with promoter methylation 33 Recently the promoter regions of BOB.1/OBF.1, CD79b and TCL1 were shown to be methylated cHL cell lines 52 . We not only substantially extend the list of the B-cell specific genes silenced by DNA methylation in cHL adding PU.1, BCMA, LCK, CD19, SYK and CD20 genes, but we also investigated the methylation status of selected genes in HRS cells isolated from primary cases of cHL.
DNA methylation is a frequent mechanism of tumor suppressor gene inactivation. There are two models to explain the gene silencing by DNA methylation. The first model considers the promoter methylation as a stochastic event. Such "methylation errors" 53 would then became inherited due to some positive effects on cell growth, similar to the selection processes known for genetic mutations. Typically, such a stochastic event would only occur in one allele. To also silence the second allele, other events like loss of heterozygosity (LOH) are likely to be involved. Examples for stochastic methylation in cHL might be the tumor suppressor genes p18INK4c 25 and RASSF1A(RAS effector) 24 . Their silencing is observed in only part of the cases and it is not specific for cHL. The second model considers methylation as a determined process. This second model predicts that functionally or structurally related genes are targeted to methylation by transcriptional silencing due to the initial down-regulation of specific transcription factor(s) 54,28,55 . The silencing of B-lineage specific genes might be an example of such a systemic gene silencing assuming the existence of common factor(s)
causing the cooperative down-regulation of all these B-cell-specific target genes. For personal use only. by on February 6, 2008. www.bloodjournal.org From PCR products were separated on the 1.5% agarose gel and visualized by EtBr-staining. All experiments were done at least in triplicate. 
